Core Insights - The article provides an objective ranking of fund net asset values, highlighting the top-performing and bottom-performing funds without subjective bias [1] Fund Performance Summary Top 10 Funds by Net Value Growth - The top-performing funds over the past 10 days include: 1. 招商沪深300地产等权重指数A with a net value of 0.3322 and a growth of 5.36% 2. 招商沪深300地产等权重指数C with a net value of 0.3308 and a growth of 5.35% 3. 国投瑞银白银期货(LOF)C with a net value of 1.5941 and a growth of 3.09% 4. 国投瑞银白银期货(LOF)A with a net value of 1.6077 and a growth of 3.09% 5. 鹏华中证800地产指数(LOF)A with a net value of 0.6282 and a growth of 3.02% 6. 鹏华中证800地产指数(LOF)C with a net value of 0.6155 and a growth of 3.01% 7. 东方阿尔法瑞享混合发起C with a net value of 1.1124 and a growth of 2.93% 8. 东方阿尔法瑞享混合发起A with a net value of 1.1125 and a growth of 2.93% 9. 泰信发展主题混合 with a net value of 1.8410 and a growth of 2.68% 10. 华夏房地产ETF联接A with a net value of 0.7161 and a growth of 2.64% [2] Bottom 10 Funds by Net Value Decline - The bottom-performing funds over the past 10 days include: 1. 华宝海外中国成长混合 with a net value of 1.3900 and a decline of 2.73% 2. 大成港股精选混合(QDII)C with a net value of 1.1909 and a decline of 2.43% 3. 大成港股精选混合(QDII)A with a net value of 1.2196 and a decline of 2.43% 4. 大成中国优势混合(QDII)C with a net value of 1.3578 and a decline of 2.30% 5. 大成中国优势混合(QDII)A with a net value of 1.3675 and a decline of 2.29% 6. 方正富邦核心优势混合C with a net value of 1.0710 and a decline of 2.16% 7. 方正富邦核心优势混合A with a net value of 1.0847 and a decline of 2.15% 8. 平安高端制造混合C with a net value of 1.6458 and a decline of 2.11% 9. 平安高端制造混合A with a net value of 1.7424 and a decline of 2.10% 10. 工银香港中小盘美 with a net value of 0.2726 and a decline of 2.08% [3] Market Analysis - The Shanghai Composite Index opened lower but rebounded, closing with a small decline. The ChiNext Index showed a similar trend, with a slight drop after filling a gap. The total trading volume was 1.79 trillion, with 2,435 stocks rising and 2,844 falling, and a涨跌停 ratio of 60:11 [5] - Leading sectors included real estate, commercial retail, engineering machinery, transportation facilities, hotel and catering, aviation, and non-ferrous metals, while banking, IT equipment, and trade agency sectors lagged [5] Fund Strategy Insights - The 招商沪深300地产等权重指数A fund showed significant net value growth, indicating a strong performance in the real estate sector [6] - The top holdings in this fund include 海南机场, 招商蛇口, 万科A, and 保利发展, with a concentration of 94.56% in the top ten holdings, reflecting a focus on the real estate industry [7] - Conversely, the 华宝海外中国成长混合 fund underperformed, with a lower concentration of 38.75% in its top holdings, indicating a diversified but less effective strategy in the current market [7]

2025年12月10日，港股市场上演"惊魂逆转"行情，早盘受外围流动性担忧拖累大幅下探，午后在南向资 金抄底与政策预期升温推动下快速反弹，主要指数全线翻红。截至发稿时间，恒生指数报25466.57点， 较前一交易日上涨32.34点，涨幅0.127%，早盘曾最低跌至25257.61点，单日振幅超400点；恒生科技指 数上涨21.83点，涨幅0.393%，早盘最大跌幅一度达2.1%；恒生中国企业指数同步反弹，报8939.42点。 反映资金午后入场积极性显著提升。 板块与个股层面，早盘领跌的科技、消费股午后集体回血。科技股中，阿里巴巴（09988.HK）早盘跌 3.8%，收盘转涨1.2%，报79.5港元，单日振幅超5%；美团-W（03690.HK）从跌2.5%反弹至涨2.1%，快 手-W（01024.HK）、百度集团-SW（09888.HK）均实现"由跌转涨"，涨幅分别达1.8%、1.5%。消费股 方面，泡泡玛特（09992.HK）午后跌幅收窄至1.3%，较早盘4.2%的跌幅显著修复；周大福 （01929.HK）、呷哺呷哺（00520.HK）午后翻红，分别涨0.8%、0.5%。此前暴跌的个股也出现反弹， 中国中冶（ ...

➢ 每日大市点评 12 月 9 日，投资者观望本周美联储议息结果，港股升势乏力。恒生指数高开后一路下跌，收盘下跌 331 点（1.3%），收 报 25,434 点；恒生科技指数下跌 107 点（1.9%），收盘报 5,554 点；全天大市成交额微增至 2,102 亿元。港股通净流入 减少至 5.3 亿元。盘面上，美国国会料通过法案，限制中资生物科技公司获得华府资助合约，生物科技医药股逆市造好， 药明生物（2269 HK）升 1.9%；药明康德（2359 HK）升 1.1%。特朗普允许英伟达向中国出售 H200 芯片，港股芯片板块 下跌，中芯国际（981 HK）和华虹半导体（1347 HK）下跌 4%-5%。内房股方面，雅居乐（3383 HK）被提出清盘呈请， 周二跌 18.4%，其他内房股受到拖累，龙湖（960 HK）跌 6%；华润置地（1109 HK）跌 3.7%；中海外（688 HK）跌 3.1%。 港股短期将维持震荡格局。 2025 年 12 月 10 日 星期三 国家统计局将于 12 月 10 日公布 11 月物价数据。市场预期，11 月食品价格上行将推动当月全国居民消费价格（CPI）同 比增速回升； ...

Core Viewpoint - WuXi Biologics (02269) has shown a fluctuating upward trend in its stock price, currently at 33.74 HKD, up 0.42%, with a five-day volatility of 11.4%, indicating active market trading and some volatility [1] Group 1: Stock Performance - The biotechnology sector is experiencing a strong performance against the market trend, with several Chinese biotech stocks performing well despite the Hang Seng Index decline on December 10, 2025 [1] - Other related companies such as WuXi AppTec (02359) and China Biologic Products (01177) saw declines of 1.15% and 2.04%, respectively [1] - Notably, the stock of Gilead Sciences (01672) surged nearly 18% due to positive results from its obesity treatment drug research, but later dropped by 3.73% [1] Group 2: Technical Analysis - WuXi Biologics' stock price is currently near the 10-day moving average (approximately 32.03 HKD) and the 30-day moving average (approximately 33.17 HKD), slightly below the 60-day moving average (approximately 35.78 HKD) [1] - The Relative Strength Index (RSI) is at a neutral level of 52, with overall technical indicators signaling a "neutral" stance, while some trend indicators like MACD and Bollinger Bands are giving buy signals [1] - Key support levels are at 31.9 HKD and 31 HKD, while resistance levels are at 35.2 HKD and 36.1 HKD, with an overall upward probability of 54% [3] Group 3: Derivative Market Insights - The performance of derivative products has been notable, with leveraged characteristics highlighted in a volatile market [4] - On December 5, when WuXi Biologics' stock rose approximately 2.88%, related derivative products showed significant price changes, with UBS bull certificates (67145) rising 18% and JPMorgan bull certificates (66081) increasing by 14% [4] - This demonstrates that even moderate increases in the underlying stock can lead to amplified returns in derivatives due to leverage [4][5] Group 4: Investment Strategies - For investors considering derivatives, various products are available to meet different investment strategies and risk preferences [7] - UBS bull certificates (67145) have a strike price of 28.8 HKD and an actual leverage of about 5 times, providing a safety margin due to its distance from the current stock price [7] - For cautious investors, UBS bear certificates (58905) with a strike price of 40 HKD and an actual leverage of about 4.6 times may serve as a hedging option [7]

市场等待本周美联储议息会议，港股三大指数今日再度走低，恒指及国指均跌超1%，恒科指数一度跌 超2%。截止收盘，恒生指数跌1.29%或331.13点，报25434.23点，全日成交额为2102.36亿港元；恒生国 企指数跌1.62%，报8936.41点；恒生科技指数跌1.9%，报5554.68点。 中金指出，关于近期港股为何在三地中走得更弱，资金面上可以找到一些解释：1）南向过去几周持续 萎缩，港股不在基准的话可能导致调仓；对比之下，港股IPO 一点不少，且上半年集中上市的大票纷纷 到了6个月解禁期；2）日央行下周加息担忧挥之不去；3）美联储本周虽然降息，但觉得也很难鸽派， 所以美债利率不降反升，诸如此类。 蓝筹股表现 药明生物(02269)领涨蓝筹。截至收盘，涨1.88%，报33.56港元，成交额14.34亿港元，贡献恒指3.64点。 交银国际指，2025年CXO整体订单和业绩复苏势头明显。该行预计，随着下游融资边际改善+出海热潮 带动上游景气度逐步进一步回升，2026年板块有望维持较快的业绩增速。但在美国药品相关监管收紧、 新药研发难度升级的长期大趋势下，行业整合或才刚拉开序幕，未来将继续淘汰落后产能及企业 ...

1. 有色金属股跌幅居前。截至收盘，江西铜业（600362）股份(00358)跌6.51%，报33.58港元；洛阳钼业 （603993）(03993)跌6.42%，报17.92港元；中国铝业（601600）(02600)跌5.69%，报10.77港元；紫金矿 业（601899）(02899)跌4.24%，报32.5港元。 盘面上，大型科技股悉数下跌，阿里巴巴跌1.63%，腾讯跌0.41%。特朗普宣布允许英伟达对华出售 H200芯片，芯片股集体走低，中芯国际跌超4%，数据中心股万国数据则涨超2%；内房股普遍下行，雅 居乐集团跌超18%；水泥、钢铁、石油、航空股等承压。另一边，部分医药股逆势走强，歌礼制药 ASC30治疗肥胖症的13周II期研究取得积极顶线结果，股价劲升18%。 市场预计日本央行将调整加息步伐；欧洲央行执委Schnabel的鹰派讲话，促使市场押注明年加息；美联 储影子主席哈塞特发表的不够鸽派的言论，同样打压明年降息预期。分析人士指出，市场几乎已消化美 联储本周降息的预期，但投资者认为其政策声明和主席鲍威尔的讲话可能暗示进一步降息的门槛提高。 市场等待本周美联储议息会议，港股三大指数今日再度走低，恒 ...

港股创新药概念走强，歌礼制药一度飙涨超20%，药明合联、药明生物、恒瑞医药等跟涨。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | | 01672 | 歌礼制药-B ● | 17.140 | +2.810 | 19.61% | | 02268 | 药明合联 | 69.700 | +2.350 | 3.49% | | 02269 | 药明生物 | 33.740 | +0.800 | 2.43% | | 01276 | 恒瑞医药 | 74.100 | +1.550 | 2.14% | | 00867 | 康哲药业 | 13.870 | +0.210 | 1.54% | | 01177 | 中国生物制药 | 6.850 | +0.070 | 1.03% | | 02096 | 先声药业 | 13.850 | +0.140 | 102% | 此番大涨背后，直接催化因素是歌礼制药昨晚公布的一项重磅临床研究结果。 研究显示，口服小分子 GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降达 7.7 ...

继11月28日推出恒生生物科技指数期货后，港交所（00388.HK）在指数业务拓展领域再添重要举措。 12月9日，港交所正式宣布推出科技100指数，同时授权内地综合性资产管理公司易方达基金，在国内推出追踪该指数的交易所买卖基金（ETF）。消息披露 后，港交所股价走势平稳，截至发稿时小幅下跌1.19%。 | 指数资料 | | | --- | --- | | 推出日期 | 2025年12月9日 | | 基日 | - 2020年12月31日 | | 基值 | 10,000 | | 货币 | 港元 | | 调整周期 | 每半年(6月及12月) | | 权重再平衡周期 | 每季度(3月、6月、9月及12月) | | 图源： 港交所官网 | | 此外，指数成份股必须符合港股通交易资格这一硬性要求。若在定期指数调整期间，某成份股不再满足港股通交易资格，将被从指数中剔除，以保障指数的 可投资性。 根据港交所披露的指数成份股名单，这100只标的全面覆盖了港股市场核心科技企业矩阵，包括腾讯（00700.HK）、阿里巴巴（09988.HK）、小米集团 （01810.HK）等互联网及科技龙头，宁德时代（03750.HK）、比亚迪（0 ...

Group 1 - Southbound capital is expected to continue flowing into the Hong Kong stock market in 2025, with a cumulative net purchase of nearly 1.4 trillion HKD in the current year, providing strong support for market liquidity and potentially resonating with the foreign capital returning during the Federal Reserve's interest rate cut cycle [1] - As of December 8, southbound capital has seen a net inflow for eight consecutive days, with the top ten individual stocks attracting this capital primarily focusing on technology, new consumption, and pharmaceuticals, including companies like Xiaomi Group, Meituan, Alibaba, Pop Mart, Leap Motor, and WuXi Biologics [1] - The Hang Seng Tech Index ETF (513180) tracks the Hang Seng Tech Index, covering 30 leading technology stocks in Hong Kong, combining both hardware and software technology, and is favored by overseas and southbound capital due to its focus on core assets in China's AI industry chain [1]

Group 1 - The Hong Kong stock market experienced fluctuations, with the Tianhong Hong Kong Technology ETF (159128) dropping by 1.67% and a trading volume exceeding 36 million yuan, while still seeing a net subscription of 30 million shares [1] - Key constituent stocks such as Horizon Robotics-W and WuXi Biologics rose over 2%, with Kingsoft Cloud, Kingsoft, and BeiGene also showing gains [1] - Despite a slight decline of 0.42% yesterday, the Tianhong Hong Kong Technology ETF (159128) attracted over 63 million yuan in net inflows, marking 17 consecutive trading days of net inflows totaling over 570 million yuan [1] Group 2 - The Tianhong Hang Seng Technology ETF (520920) also saw a decline of 1.58% with a trading volume exceeding 240 million yuan, while experiencing net inflows for 28 consecutive trading days, accumulating over 5 billion yuan [1] - The Tianhong Hang Seng Technology ETF (520920) closely tracks the Hang Seng Technology Index and can invest in quality tech companies not included in the Hong Kong Stock Connect through the QDII mechanism [2] - According to Zhongyin International, recent market volatility is normal in a bull market, and short-term fluctuations do not alter the upward trend of the Hong Kong stock market [2]